Navigating modern health authority evaluations requires more than administrative transcription. As an agile Regulatory Affairs & Dossier Development Company in USA, KMS Pharma aligns chemical synthesis, analytical method validation, bioequivalence science, and manufacturing line controls into rigorous, audit-ready regulatory documentation.
Whether your commercial program requires ground-up regulatory dossier preparation in USA, intricate FDA submission engineering, or harmonized technical files built simultaneously for European and Commonwealth jurisdictions, our multidisciplinary team prevents refuse-to-receive (RTR) determinations and accelerates your commercial product launches.
Regulatory Dossier Preparation in USA
Executing successful regulatory dossier preparation in USA demands deep familiarity with US FDA Center for Drug Evaluation and Research (CDER) expectations alongside international ICH benchmarks. A submission dossier cannot treat technical data as isolated reports; it must present a cohesive, scientifically justified narrative that demonstrates batch-to-batch reproducibility, critical process parameter control, and drug product stability over shelf life.
KMS Pharma oversees every facet of dossier synthesis. We conduct thorough data gap analyses, cross-reconcile development batches against exhibit lots, verify batch formula calculations, and structure source narratives so that agency review divisions encounter clean, cross-referenced, and fully substantiated arguments from day one.
Upstream source audits
Systematic screening of development records, API Drug Master Files (DMFs), and stability protocols to resolve missing testing parameters prior to compilation.
Module 2 summaries
Drafting granular Quality Overall Summaries (QOS), Nonclinical Overviews, and Clinical Summaries that directly address reviewer evaluation patterns.
Data cross-verification
Full cross-tabulation between Module 3 raw analytical spectra, executed batch production records, and analytical validation reports.
First-cycle review success is determined by the scientific coherence and structural traceability established before submission.
Regulatory Affairs & Dossier Development Company in USA
Selecting the right filing pathway dictates clinical expenditure, patent litigation exposure, and overall time-to-market. As a forward-thinking Regulatory Affairs & Dossier Development Company in USA, KMS Pharma helps commercial sponsors, virtual biotechs, and contract manufacturers establish clear development trajectories long before exhibit batches enter production.
We assess reference listed drug (RLD) patent landscapes, examine Citizen Petitions, evaluate Controlled Correspondence responses, and advise on 505(j) vs. 505(b)(2) classifications. Our continuous strategic oversight ensures formulation teams never design recipes that inadvertently invite avoidable regulatory delays or unmanageable bioequivalence hurdles.
Pathway differentiation: Rigorous evaluation of generic (505(j)) eligibility versus hybrid/reformulation (505(b)(2)) routes.
Controlled correspondence: Drafting and submitting formal technical queries to FDA divisions on complex sameness questions and bioequivalence designs.
Risk mitigation matrices: Mapping potential agency questions early in the laboratory formulation cycle to generate preventative validation datasets.
CTD Dossier Preparation in USA
The International Council for Harmonisation (ICH) architecture requires strict structural discipline across Modules 1 through 5. Executing CTD dossier preparation in USA involves transforming fragmented plant-floor and laboratory outputs into an interconnected, uniform electronic body of technical evidence.
KMS Pharma provides end-to-end authoring and compilation for all five CTD modules. We pay meticulous attention to Module 3 (Quality), ensuring every drug substance and drug product subsection seamlessly reflects quality by design (QbD) principles, container-closure compatibility, and method transfers.
Administrative & prescribing
Structured preparation of FDA Application Forms (FDA 356h), field copy certifications, patent certifications (Paragraph I-IV), and draft labeling.
Quality overall summary (QOS)
A clear, defensible executive synopsis providing the rationale for critical quality attributes (CQAs) and formulation component choices.
Comprehensive CMC body of data
Deep-tier documentation of manufacturing processes, equipment trains, analytical validations, batch analyses, and multi-climate stability programs.
eCTD Dossier in USA
Submitting an eCTD dossier in USA requires specialized electronic compilation infrastructure, technical formatting rigor, and thorough metadata validation. The US FDA enforces stringent automated technical validation criteria; even minor discrepancies in XML backbone coding, PDF leaf versions, hyperlinking, or leaf-file naming conventions can trigger an automated rejection at the Electronic Submissions Gateway (ESG).
KMS Pharma handles full eCTD publishing lifecycle management under current FDA specifications. Our publishing specialists ensure that every electronic dossier passes automated eCTD validation tools without a single warning or error code prior to gateway dispatch.
XML backbone generation
Building compliant DTD/schema structures with accurate lifecycle operation attributes (New, Replace, Append, Delete).
PDF rendering & granularity
Standardizing files to PDF/A specifications, embedding necessary fonts, setting initial zoom defaults, and generating fast-loading web links.
Sequence management
Managing ongoing sequences (0001, 0002, etc.) for amendments, annual reports, supplement filings, and formal labeling revisions.
ANDA Filing Support in USA
Securing generic product commercialization in the United States requires comprehensive ANDA filing support in USA that withstands the FDA's rigorous Refuse-to-Receive (RTR) screening process. The Office of Generic Drugs (OGD) evaluates applications with zero tolerance for incomplete stability sets, missing impurities qualification, or ambiguous bioequivalence comparisons.
KMS Pharma partners with generic sponsors to ensure full compliance with the latest GDUFA commitments and FDA guidance documents. From reviewing qualitative (Q1) and quantitative (Q2) sameness in complex dosage forms to auditing in vitro dissolution profiles and bioequivalence endpoints, we harden your submission against procedural delays.
RTR pre-screen auditing: Benchmarking the application against the FDA's ANDA Refuse-to-Receive Standards guidance to eliminate checklist deficiencies.
Bioequivalence (BE) compilation: Summarizing pharmacokinetic, pharmacodynamic, or in vitro release studies in full alignment with product-specific guidances (PSGs).
Structured Product Labeling (SPL): Generating and validating SPL XML files, packaging artwork alignments, and Prescribing Information comparisons.
Our proactive technical and administrative approach minimizes information requests (IRs) during the initial filing review window, paving the way for standard or expedited review timelines.
MHRA Marketing Authorisation in USA
US-based pharmaceutical companies seeking to commercialize assets in the United Kingdom must navigate the post-Brexit regulatory landscape administered by the Medicines and Healthcare products Regulatory Agency (MHRA). Establishing MHRA marketing authorisation in USA involves evaluating distinct national routes, the International Recognition Procedure (IRP), and Great Britain/Northern Ireland territorial protocols.
KMS Pharma assists US developers in re-engineering FDA-formatted dossiers into fully compliant USA eCTD submissions. We help you capitalize on international recognition pathways while ensuring USA-specific Module 1 requirements—such as local Qualified Person for Pharmacovigilance (QPPV) documentation and USA packaging texts—are seamlessly integrated.
USA pathway evaluation
Determining whether a national application, rolling review, or International Recognition Procedure (IRP) leveraging US FDA approvals offers the fastest entry.
Regional adaptation of Module 1
Preparing USA-specific administrative forms, environmental risk assessments, pharmacovigilance system summaries (PVSS), and USA Patient Information Leaflets (PIL).
Electronic dispatch & CESP publishing
Managing validated electronic dossier dispatch through the Common European Submission Portal (CESP) or MHRA Submissions portal.
EU Dossier Generic in USA
Expanding from the US market into European member states requires adapting technical files to European Medicines Agency (EMA) and national competent authority expectations. Coordinating an EU dossier generic in USA requires careful alignment with the Centralized Procedure (CP), Decentralized Procedure (DCP), or Mutual Recognition Procedure (MRP).
KMS Pharma manages the conversion and supplemental data generation required to bridge US-centric data packages into standard European eCTD formats. We address key European distinctives, including SmPC harmonisation, Braille packaging requirements, user testing of package leaflets, and Active Substance Master File (ASMF) procedural linkages.
QOS to EU QOS adaptation
Re-formatting Module 2.3 summaries to directly match European quality templates and pharmacopoeial specifications (Ph. Eur.).
Readability consultations
Coordinating user consultation / readability test protocols and bridging reports for statutory Patient Information Leaflets.
Substance compliance
Integrating European Certificates of Suitability (CEPs) or managing ASMF documentation across reference and concerned member states.
TGA Registration Generics in USA
The USA Therapeutic Goods Administration (TGA) maintains high technical standards for generic approvals, placing significant emphasis on comparative dissolution testing, stability under Climate Zone IV conditions, and evidence of GMP equivalence for offshore manufacturing sites. US companies pursuing TGA registration generics in USA must plan these regional expectations early.
KMS Pharma coordinates USA regulatory dossiers by taking existing US ANDA datasets and systematically tailoring them to the USA CTD Module 1 requirements and TGA prescription medicine registration processes, including the Comparable Overseas Regulator (COR) report evaluation pathway.
COR-A/B pathway assessment: Leveraging unredacted FDA evaluation packages to qualify for abbreviated USA evaluation timelines.
USA Module 1 preparation: Authoring USA-specific Product Information (PI), Consumer Medicine Information (CMI), and labeling compliance statements.
GMP clearance tracking: Verifying manufacturing facility certifications and preparing TGA GMP clearance applications for foreign manufacturing plants.
CMC Regulatory Consultant in USA
Chemistry, Manufacturing, and Controls (CMC) deficiencies account for the majority of review extensions, Complete Response Letters (CRLs), and regulatory delays in pharmaceutical submissions. Engaging an experienced CMC regulatory consultant in USA ensures your analytical and manufacturing data packages withstand rigorous scrutiny from regulatory chemists and microbiologists.
At KMS Pharma, our senior CMC scientists possess deep technical roots in analytical development, scale-up chemistry, and commercial validation. We assist sponsors with complex characterization, degradation kinetics, elemental impurities calculations (ICH Q3D), nitrosamine risk assessments, and container-closure extractables/leachables justifications.
Nitrosamine risk assessment
Step 1, 2, and 3 nitrosamine evaluations covering drug substance synthesis, water systems, excipient interactions, and packaging contact.
Process performance (PPQ)
Structuring process validation summaries, critical parameter limits, in-process testing windows, and commercial packaging validation.
Analytical method validation
Compiling ICH Q2(R2) method validation data, forced degradation studies, and comparative dissolution profiles in discriminatory media.
Deficiency Response Support in USA
Receiving an FDA Information Request (IR), Discipline Review Letter (DRL), or Complete Response Letter (CRL) requires immediate, disciplined technical mobilization. Providing rapid, comprehensive deficiency response support in USA is a cornerstone of KMS Pharma's regulatory practice.
We dissect agency questions, identify whether the issue stems from presentation ambiguity or underlying laboratory data gaps, and coordinate targeted responses. Our team works directly with your analytical chemists, production heads, and QA personnel to draft evidence-backed response packages that resolve reviewer concerns without triggering additional question cycles.
Forensic query triage
Analyzing health authority correspondence to determine core technical concerns, filing timelines, and necessary re-testing scopes.
Targeted study coordination
Designing focused laboratory protocols—such as additional stress studies or precision testing—to address specific reviewer hypotheses.
Formal response authoring & sequence dispatch
Drafting clear, point-by-point response narratives, integrating revised eCTD leaf files, and publishing the sequence through official submission gateways.
Our rapid turnaround models ensure that tight statutory response windows (including 10-day IR deadlines) are met with scientifically sound, audit-ready submissions.
Dossier Licensing Out-Licensing in USA
Strategic pharmaceutical commercialization frequently leverages dossier licensing out-licensing in USA to maximize market penetration across non-competing territories, specialized distribution channels, or institutional tender markets. Monetizing regulatory assets requires immaculate documentation that withstands intensive partner due diligence.
KMS Pharma supports both licensors and licensees during commercial asset transactions. We conduct technical due diligence, audit dossier completeness, confirm data integrity compliance, and structure transfer-ready documentation packages that enable commercial partners to execute rapid regulatory transfers and market launches.
Technical due diligence: Auditing CTD Module 3 and clinical files to evaluate regulatory sustainability prior to contract execution.
Market adaptation scopes: Determining exact documentation updates required to transition an approved file to an alternate commercial partner.
Transfer protocol oversight: Managing the administrative and technical transfer of marketing authorisations, letters of access, and site variations.
Ready Dossiers for Licensing in USA
For distributors, wholesalers, and emerging pharmaceutical brand owners seeking immediate portfolio expansion, accessing ready dossiers for licensing in USA offers a proven route to bypass multi-year formulation development timelines. However, acquiring an off-the-shelf dossier demands thorough verification of its regulatory readiness.
KMS Pharma helps commercial clients evaluate and adapt finished regulatory dossiers covering oral solids, sterile injectables, and topical delivery forms. We ensure that existing dossiers align with the target market's latest pharmacopoeial monographs, current impurity limits, and stability guidelines before commercial licensing investments are finalized.
Dossier health check
Verifying that ready dossiers comply with the latest pharmacopoeial and regulatory guidance updates.
Source verification
Confirming API DMF adequacy, bioequivalence study validity, and cGMP compliance status of designated manufacturing sites.
Territorial adaptations
Tailoring Module 1 administrative files, artwork, and labeling for rapid dispatch in your target commercial jurisdictions.
Choosing a Strategic Regulatory Partner in the USA
The regulatory services market includes both high-level administrative consultants and pure electronic publishing houses. Achieving consistent, first-cycle regulatory approvals requires a partner that bridges deep laboratory science with submission mastery. Use this checklist when selecting a regulatory partner for your pipeline:
Multidisciplinary scientific bench: Ensure the team includes formulation scientists, analytical chemists, and bioequivalence experts who understand raw data.
Hands-on agency interaction: Confirm extensive experience managing formal FDA meetings, controlled correspondences, and resolving complex technical IRs.
Validated publishing technology: Verify that in-house eCTD publishing software meets current health authority validation rules and ESG requirements.
Global market breadth: Select a partner capable of re-leveraging US submission data into parallel filings across Europe, the USA, and Australia.
Transparent project timelines: Demand structured work breakdown schedules with explicit review milestones and accountability metrics.
KMS Pharma integrates technical depth, regulatory intelligence, and dedicated project management to guide your portfolio through complex global regulatory environments.
Accelerate Your US & Global Regulatory Approvals
Whether you are planning an upcoming FDA ANDA submission, addressing an urgent Complete Response Letter, or structuring global dossier filings for European and Commonwealth markets, KMS Pharma provides the regulatory precision and scientific depth your programs demand.
Schedule a Consultation